Evanthia Roussos Torres, MD, PhD

Dr. Roussos Torres received a BS in Microbiology, Immunology and Molecular Genetics and a
BA in World Arts and Cultures with a concentration in Dance from the University of California
at Los Angeles (UCLA). She then went on to receive her combined MD/PhD from the Medical
Scientist Training Program at the Albert Einstein College of Medicine in New York. She then
completed her internal medicine residency at the Hospital of the University of Pennsylvania and
her hematology/ oncology fellowship training at the University of Pennsylvania and Johns
Hopkins University. Dr. Roussos Torres graduated from fellowship and began her faculty career
as an Assistant Professor at Johns Hopkins University and is now an Assistant Professor at the
University of Southern California where she leads her own lab and works collaboratively with
other physicians and physician scientists to continue her work in immune-oncology with a
specific interest in breast cancer and the tumor immune suppressive microenvironment.

Dr. Roussos Torres is very passionate about her research as well as her care of patients with
cancer and training of the fellows to become compassionate and knowledgeable physicians. She
is driven to make memorable contributions to the field of cancer research given her personal
experience advocating for her mother who died from metastatic breast cancer in 2016. Dr.
Roussos Torres felt passionate about having an impact on the field of breast cancer prior to her
mother’s diagnosis but learning about the devastation of metastatic disease as the family member
of a patient provided a different perspective and drive for novel treatment options.

Dr. Roussos Torres loves her work but also prioritizes her family life; her husband Dr. Stephen
Torres is an orthopedic surgeon, specializing in sports medicine and together they have three
sons, Owen, James and Luke who fill their life with joy and make every day a wonder! The
Torres family also has a Chesapeake Bay retriever, Emma who greatly contributes to her active
lifestyle! Dr. Roussos Torres enjoys traveling, eating out at new restaurants and road biking! Dr.
Roussos Torres grew up in Santa Monica and is so happy to work close to where she grew up to
raise her family near her siblings, their families, and her father who still resides here.

Laboratory website: https://sites.usc.edu/roussostorreslab/

Publications library: https://www-ncbi-nlm-nihgov.libproxy2.usc.edu/myncbi/1pwdQqmmnMeUHt/bibliography/public/

• Clocking cancer: the circadian clock as a target in cancer therapy Oncogene. 2021 05; 40(18):3187-3200. . View in PubMed
• Adopting an alternative structure for clinical trials in immunotherapy Expert Rev Anticancer Ther. 2021 04; 21(4):373-375. . View in PubMed
• Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response Front Mol Biosci. 2021; 8:674558. . View in PubMed
• Evaluating the impact of age on immune checkpoint therapy biomarkers Cell Rep. 2021 08 24; 36(8):109599. . View in PubMed
• Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) Clin Cancer Res. 2021 11 01; 27(21):5828-5837. . View in PubMed
• Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity bioRxiv. 2021. . View in PubMed
• Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach JCO Oncol Pract. 2020 Oct; 16(10):665-674. . View in PubMed
• Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-16. . View in PubMed
• Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide Oncoimmunology. 2020 05 14; 9(1):1760685. . View in PubMed
• Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors Front Bioeng Biotechnol. 2020; 8:141. . View in PubMed
• A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity Cancer Immunol Res. 2019 03; 7(3):428-442. . View in PubMed
• Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data Cancer Res. 2019 10 01; 79(19):5102-5112. . View in PubMed
• Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs Cancer Immunol Res. 2018 12; 6(12):1561-1577. . View in PubMed
• Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer Current Breast Cancer Reports. 2018. . View in PubMed
• N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors J Cell Sci. 2012 Feb 01; 125(Pt 3):724-34. . View in PubMed
• Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging Nat Protoc. 2011 Sep 08; 6(10):1500-20. . View in PubMed
• Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM Clin Exp Metastasis. 2011 Aug; 28(6):515-27. . View in PubMed
• Chemotaxis in cancer Nat Rev Cancer. 2011 Jul 22; 11(8):573-87. . View in PubMed
• Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer J Cell Sci. 2011 Jul 01; 124(Pt 13):2120-31. . View in PubMed
• AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment Cancer Res. 2010 Oct 01; 70(19):7360-4. . View in PubMed
• Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors Breast Cancer Res. 2010; 12(6):R101. . View in PubMed
• Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase Cancer Res. 2009 Dec 01; 69(23):8868-76. . View in PubMed
• A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis Dev Cell. 2008 Dec; 15(6):813-28. . View in PubMed
• Genetic analysis of the diabetes-prone C57BLKS/J mouse strain reveals genetic contribution from multiple strains Biochim Biophys Acta. 2006 Apr; 1762(4):440-6. . View in PubMed
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res. 2003 Mar; 9(3):1136-44. . View in PubMed
• Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma Cancer Genet Cytogenet. 2002 Aug; 137(1):43-8. . View in PubMed

• Lenz, Heinz-Josef